Back to Resource Center

Nonclinical Pharmacology/Toxicology Development of Topical Drugs Intended to Prevent the Transmission of Sexually Transmitted Diseases (STD) and/or for the Development of Drugs Intended to Act as Vaginal Contraceptives

Nonclinical Pharmacology/Toxicology Development of Topical Drugs Intended to Prevent the Transmission of Sexually Transmitted Diseases (STD) and/or for the Development of Drugs Intended to Act as Vaginal Contraceptives

July 2005

Click to view Guidance Document

Click for full info +

Nonclinical Pharmacology/Toxicology Development of Topical Drugs Intended to Prevent the Transmission of Sexually Transmitted Diseases (STD) and/or for the Development of Drugs Intended to Act as Vaginal Contraceptives

July 2005
In this Technical Brief:
Health Risk(s):
  • STDs
  • Vaginal Contraceptives
Product Type(s):

  • Combination
  • Vaginal Contraceptives
  • Topical Drugs
Topic(s):

  • Pharmacology / Toxicology
  • Regulatory Issues
Region(s):

  • United States

Full Info:


Resource Type:

Guidance Document

Citation:

Division of Reproductive and Urologic Drug Products, Office of Drug Evaluation II, Division of Anti-infective Drug Products
and Division of Antiviral Drug Products, Office of Drug Evaluation IV (2005)

Authors:

Division of Reproductive and Urologic Drug Products, Office of Drug Evaluation II, Division of Anti-infective Drug Products and Division of Antiviral Drug Products, Office of Drug Evaluation IV

Health Risks(s):

  • STI / STD
  • Unintended Pregnancy

Product type(s):

  • Contraceptives
  • MPTs

Topic(s):

  • MPTs
  • Development
  • Regulatory

Region(s)

  • United States

URL of resource:

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-pharmacologytoxicology-development-topical-drugs-intended-prevent-transmission-sexually

Back to Resource Center